Syngene International Releases Unaudited Financial Results for Quarter Ended June 30, 2026

Syngene International Releases Unaudited Financial Results for Quarter Ended June 30, 2026

Syngene International Releases Unaudited Financial Results for Quarter Ended June 30, 2026​

Syngene International Limited has disclosed its unaudited financial results for the quarter ended June 30, 2026, presenting both standalone and consolidated figures. The results provide insights into the company's operational performance across various segments and activities during this period.

The Board of Directors reviewed and approved these results at a meeting held on July 29, 2026.

Standalone Financial Performance Overview​

The unaudited standalone financial results for Syngene International Limited (in Rs. million) show key movements in income and expenses for the quarter ended June 30, 2026, compared to the preceding three months of March 31, 2026, and the corresponding period in the previous year (June 30, 2025).

Particulars3 Months Ended 30 June 2026 (Unaudited)Preceding 3 Months Ended 31 March 2026 (Audited)Corresponding 3 Months Ended June 30, 2025 (Unaudited)
Revenue from operations6,6309,6007,993
Other Income248216166
Total Income6,8789,8168,159
Cost of chemicals, reagents and consumables consumed1,5852,0222,230
Changes in inventories of finished goods and work-in-progress(48)98(219)
Employee benefits expense2,0702,4852,126
Finance costs416559
Depreciation and amortisation expense956953946
Other expenses1,7591,9252,127
Foreign exchange fluctuation loss, net48022748
Total expenses6,8437,7757,317
Profit before tax and exceptional items352,041842
Exceptional Items, net gain/(loss)(135)(74)-
Profit before tax(100)1,967842
Total tax expense(79)485102
Profit for the period(21)1,482740

Consolidated Financial Performance Highlights​

The consolidated financial results reflect the performance of Syngene International Limited and its subsidiaries. For the three months ended June 30, 2026, the Group reported the following:

Particulars3 Months Ended 30 June 2026 (Unaudited)Preceding 3 Months Ended 31 March 2026 (Audited)Corresponding 3 Months Ended June 30, 2025 (Unaudited)
Revenue from operations7,36010,3658,745
Other Income253222177
Total Income7,61310,5878,922
Cost of chemicals, reagents and consumables consumed1,7822,2332,395
Changes in inventories of finished goods and work-in-progress(48)98(219)
Employee benefits expense2,5913,0082,617
Finance costs96121116
Depreciation and amortisation expense1,1221,1151,112
Other expenses1,6261,7811,840
Foreign exchange fluctuation loss, net50121148
Total expenses7,6708,5677,909
Profit before tax and exceptional items(57)2,0201,013

Corporate Updates and Operational Developments​

The company provided several updates regarding its business operations and corporate actions:

  • Subsidiary Liquidation: The Board of Directors approved the voluntary liquidation of wholly owned subsidiary, Syngene Manufacturing Solutions Limited (SMSL), which was subsequently approved by shareholders.
  • Employee Benefits and Dividends: A final dividend of Rs. 1.25 per equity share of Rs. 10/- was recommended by the Board of Directors on April 29, 2026, subject to shareholder approval in the Annual General Meeting.
  • Business Developments:
* One note highlighted that during the quarter ended June 30, 2025, Syngene USA Inc., a subsidiary, acquired a biologics site with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC. This acquisition is noted as increasing the company's total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services.
* The management also provided details regarding the re-assessment of the impact of new labour codes for which a credit was reported in the standalone financial results during the quarter ended March 31, 2026.
* For the quarter ended June 30, 2026, an additional amount of Rs. 135 million pertaining to termination benefits was recognized and disclosed under 'Exceptional Items'.

SYNGENE Stock Price Movement​

Syngene International Limited shares settled today after edging higher, gaining 1.06% to close at ₹414.25. The stock completed the trading day with a total volume of 1.22 million shares, having traded within a range between a low of ₹406 and a high of ₹417.5.
 

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.

Back
Top